Skip to main content

Table 1 Characteristics of the 75 mRCC patients at baseline

From: Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

Characteristics
Sex, n (%)
 Male 60 (80)
 Female 15 (20)
Age, years
 Median (range) 55 (36–85)
Smokers (current or past), n (%) 36 (48)
Histology, n (%)
 Clear cell carcinoma 56 (74.7)
 Papillary cell carcinoma 8 (10.7)
 Mixt cell carcinoma 6 (8)
 Sarcomatoid cell carcinoma 3 (4)
 Bellini carcinoma 1 (1.3)
 Chromophobic cell carcinoma 1 (1.3)
Nephrectomy, n (%) 70 (93.3)
Fuhrman grade, n (%)
 1 1 (2)
 2 11 (22)
 3 25 (50)
 4 13 (26)
 Missing 25
Primary metastases, n (%) 18 (31)
 Missing 17
Bone metastases, n (%) 20 (55.6)
 Missing 39
Time to metastases, months
 Median (range) 23 (0.2-118.4)
 Missing 35
ECOG-PS, n (%)
 0 24 (32)
  ≥ 1 51 (68)
Post mTORi anti-cancer treatment 30 (46)
 Missing 33
  1. ECOG-PS Eastern Cooperative Oncology Group performance status